SCHEMBL7522154

SCHEMBL7522154

CCC[C@H]1CC[C@H](C(=O)Cl)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.41
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
LMNA P02545 3/20 0.39
MAPT P10636 3/20 0.39
ALDH1A1 P00352 2/20 0.39
PKM P14618 1/20 0.39
HTT P42858 2/20 0.39
MAPK1 P28482 1/20 0.39
TLR4 O00206 1/20 0.39
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C19 P33261 1/20 0.37
TP53 P04637 1/20 0.36
THRA P10827 1/20 0.36
THRB P10828 1/20 0.36
IDH1 O75874 1/20 0.34
PLG P00747 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4482942 1.00 CYP2C9 (0.41) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL9405948 0.94 TLR4 (0.46) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL5069945 0.94 TLR4 (0.46) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL1674729 0.94 TLR4 (0.46) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL3627200 0.94 TLR4 (0.46) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL10555723 0.89 CYP2C9 (0.37) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL10555731 0.89 CYP2C9 (0.37) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL10555735 0.89 CYP2C9 (0.37) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL1508098 0.88 HTT (0.53) CYP2C9POLBHPGDLMNAMAPT
SCHEMBL1284003 0.88 HTT (0.53) CYP2C9POLBHPGDLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109071458-B Triamide compounds and compositions comprising the same 美利肯公司 2021-12-10 CN disclosed
EP-3426639-B1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2021-05-05 EP disclosed
US-10844006-B2 Trisamide compounds and compositions comprising the same MILLIKEN & COMPANY (US) 2020-11-24 US disclosed
US-20170260129-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME MILLIKEN & CO (US) 2017-09-14 US disclosed
US-20140088124-A1 IMIDAZOLE DERIVATIVES INTERVET INC. 2014-03-27 US disclosed
US-8389073-B2 Four-ring liquid crystal compound having tetrahydropyran and 2,2′,3,3′-tetrafluorobiphenyl, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2013-03-05 US disclosed
US-20110297881-A1 FOUR-RING LIQUID CRYSTAL COMPOUND HAVING TETRAHYDROPYRAN AND 2,2',3,3'-TETRAFLUOROBIPHENYL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CHISSO PETROCHEMICAL CORPORATION (JP) 2011-12-08 US disclosed
WO-2010106550-A2 A PROCESS FOR THE PREPARATION OF N-[[TRANS-4-(1-METHYLETHYL)CYCLOHEXYL]CARBONYL]-D-PHENYLALANINE NEULAND LABORATORIES LTD. (IN) 2010-09-23 WO disclosed
US-7488832-B2 e.g. N-[amino(imino)methyl]-2-[2-(4-phenoxyphenyl)-5-phenyl-1H-pyrrol-1-yl]acetamide; beta -amyloid deposits and neurofibrillary tangles; cognition activator, neurodegenerative diseases; Alzheimer's disease, Down's syndrome WYETH (US) 2009-02-10 US disclosed
US-20080287424-A1 AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS WYETH (US) 2008-11-20 US disclosed
EP-0300009-A1 LIQUID CRYSTALLINE MIXTURE. MERCK PATENT GMBH (DE) 1989-01-25 EP disclosed
EP-0293910-A2 Liquid crystal composition and liquid crystal device containing same CANON KABUSHIKI KAISHA (JP) 1988-12-07 EP disclosed
WO-1988005803-A1 LIQUID CRYSTALLINE MIXTURE MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 1988-08-11 WO disclosed
US-4713197-A Nitrogen-containing heterocyclic compounds MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1987-12-15 US disclosed
US-4683078-A LIQUID CRYSTAL DIELECTRICS CHISSO CORPORATION (JP) 1987-07-28 US disclosed
US-4673529-A LIQUID CRYSTALS JLMOKOUM INTEGRATED CIRCUITS CHISSO CORPORATION (JP) 1987-06-16 US disclosed
US-4487954-A LIQUID CRYSTALS CHISSO CORPORATION (JP) 1984-12-11 US disclosed
US-4473487-A 4-Fluorobiphenyl derivatives, their preparation, and dielectrics and electro-optical display element containing them MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1984-09-25 US disclosed
US-4472592-A CYCLOHEXYL PHENYL ESTERS DAINIPPON INK AND CHEMICALS, INC. (JP) 1984-09-18 US disclosed
US-4290905-A FOR LIQUID CRYSTAL DISPLAYS KABUSHIKI KAISHA SUWA SEIKOSHA (JP) 1981-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10844006-B2 Trisamide compounds and compositions comprising the same TELO2, TERT, H1-2 CYP2C9 4183/4885POLB 1401/4885HPGD 3763/4885
US-20080287424-A1 AZOLYLACYLGUANIDINES AS beta-SECRETASE INHIBITORS BACE1, BACE2, APP CYP2C9 1152/4885POLB 3725/4885HPGD 2234/4885
US-20140088124-A1 IMIDAZOLE DERIVATIVES DGAT1, DGAT2, SOAT1 CYP2C9 2703/4885POLB 4112/4885HPGD 881/4885
US-20170260129-A1 TRISAMIDE COMPOUNDS AND COMPOSITIONS COMPRISING THE SAME TELO2, TERT, H1-2 CYP2C9 4183/4885POLB 1401/4885HPGD 3763/4885
US-20110297881-A1 FOUR-RING LIQUID CRYSTAL COMPOUND HAVING TETRAHYDROPYRAN AND 2,2',3,3'-TETRAFLUOROBIPHENYL, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE CCT4, TEC, TCF4 CYP2C9 343/4885POLB 4069/4885HPGD 4186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.